Zydus Lifesciences Ltd
In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 14,253 crores in FY20.
Adhering to its brand promise of being dedicated to life in all its dimensions, Zydus continues to innovate with an unswerving focus to address the unmet healthcare needs. Simultaneously it rededicates itself to its mission of creating healthier, happier communities across the globe
- Market Cap ₹ 92,790 Cr.
- Current Price ₹ 922
- High / Low ₹ 1,032 / 483
- Stock P/E 28.4
- Book Value ₹ 185
- Dividend Yield 0.65 %
- ROCE 15.0 %
- ROE 13.7 %
- Face Value ₹ 1.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 17.8%
Cons
- Stock is trading at 4.98 times its book value
- The company has delivered a poor sales growth of 7.68% over past five years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
5,263 | 6,358 | 7,224 | 8,651 | 9,427 | 9,376 | 11,905 | 13,166 | 14,253 | 14,404 | 15,110 | 17,237 | 19,024 | |
4,177 | 5,228 | 6,021 | 6,896 | 7,095 | 7,474 | 9,074 | 10,174 | 11,455 | 11,013 | 11,768 | 13,378 | 14,015 | |
Operating Profit | 1,086 | 1,130 | 1,203 | 1,756 | 2,332 | 1,902 | 2,831 | 2,991 | 2,798 | 3,391 | 3,342 | 3,860 | 5,009 |
OPM % | 21% | 18% | 17% | 20% | 25% | 20% | 24% | 23% | 20% | 24% | 22% | 22% | 26% |
49 | 32 | 30 | 45 | 112 | 127 | 111 | 183 | -264 | -231 | 2,581 | -422 | -432 | |
Interest | 183 | 169 | 90 | 68 | 53 | 45 | 91 | 194 | 342 | 159 | 127 | 130 | 74 |
Depreciation | 158 | 185 | 201 | 287 | 292 | 373 | 539 | 599 | 696 | 670 | 713 | 723 | 737 |
Profit before tax | 794 | 809 | 942 | 1,446 | 2,099 | 1,612 | 2,312 | 2,382 | 1,495 | 2,331 | 5,084 | 2,585 | 3,765 |
Tax % | 14% | 15% | 11% | 18% | 8% | 8% | 24% | 22% | 21% | 8% | 10% | 23% | |
681 | 690 | 836 | 1,188 | 1,964 | 1,517 | 1,810 | 1,899 | 1,204 | 2,185 | 4,618 | 2,092 | 3,085 | |
EPS in Rs | 6.37 | 6.38 | 7.85 | 11.24 | 18.89 | 14.53 | 17.35 | 18.06 | 11.49 | 20.84 | 43.83 | 19.37 | 29.38 |
Dividend Payout % | 24% | 24% | 23% | 21% | 17% | 22% | 20% | 19% | 30% | 17% | 6% | 31% |
Compounded Sales Growth | |
---|---|
10 Years: | 10% |
5 Years: | 8% |
3 Years: | 7% |
TTM: | 17% |
Compounded Profit Growth | |
---|---|
10 Years: | 14% |
5 Years: | 6% |
3 Years: | 17% |
TTM: | 57% |
Stock Price CAGR | |
---|---|
10 Years: | 17% |
5 Years: | 23% |
3 Years: | 18% |
1 Year: | 78% |
Return on Equity | |
---|---|
10 Years: | 22% |
5 Years: | 19% |
3 Years: | 21% |
Last Year: | 14% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 102 | 102 | 102 | 102 | 102 | 102 | 102 | 102 | 102 | 102 | 102 | 101 | 101 |
Reserves | 2,484 | 2,842 | 3,337 | 4,149 | 5,597 | 6,858 | 8,642 | 10,284 | 10,273 | 12,890 | 16,897 | 17,415 | 18,632 |
2,289 | 2,918 | 2,700 | 2,651 | 2,442 | 5,207 | 5,407 | 7,899 | 7,986 | 4,608 | 4,221 | 1,195 | 192 | |
1,548 | 1,512 | 1,847 | 2,144 | 2,208 | 2,937 | 3,632 | 4,945 | 5,115 | 6,165 | 6,421 | 6,851 | 6,955 | |
Total Liabilities | 6,423 | 7,374 | 7,986 | 9,047 | 10,350 | 15,104 | 17,783 | 23,231 | 23,477 | 23,765 | 27,642 | 25,562 | 25,879 |
2,857 | 3,026 | 3,124 | 3,352 | 3,748 | 5,755 | 6,483 | 12,164 | 12,230 | 12,133 | 12,188 | 11,521 | 11,576 | |
CWIP | 484 | 736 | 892 | 798 | 951 | 1,543 | 1,527 | 837 | 742 | 783 | 726 | 1,201 | 1,220 |
Investments | 24 | 114 | 87 | 154 | 416 | 435 | 746 | 674 | 765 | 830 | 3,288 | 1,547 | 1,675 |
3,058 | 3,498 | 3,885 | 4,743 | 5,235 | 7,371 | 9,028 | 9,556 | 9,740 | 10,019 | 11,439 | 11,294 | 11,409 | |
Total Assets | 6,423 | 7,374 | 7,986 | 9,047 | 10,350 | 15,104 | 17,783 | 23,231 | 23,477 | 23,765 | 27,642 | 25,562 | 25,879 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
511 | 603 | 903 | 994 | 1,894 | 1,312 | 919 | 1,282 | 2,932 | 3,294 | 2,104 | 2,689 | |
-1,200 | -682 | -438 | -465 | -860 | -2,872 | -974 | -3,977 | -1,004 | -837 | -1,018 | 1,178 | |
860 | 286 | -529 | -351 | -935 | 2,316 | 52 | 1,885 | -1,528 | -2,548 | -868 | -4,400 | |
Net Cash Flow | 171 | 207 | -64 | 178 | 99 | 756 | -3 | -811 | 399 | -90 | 219 | -534 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 64 | 55 | 57 | 67 | 68 | 89 | 98 | 110 | 94 | 79 | 81 | 94 |
Inventory Days | 234 | 191 | 184 | 175 | 158 | 193 | 211 | 208 | 207 | 246 | 245 | 197 |
Days Payable | 117 | 103 | 123 | 125 | 154 | 165 | 167 | 149 | 152 | 168 | 141 | 123 |
Cash Conversion Cycle | 181 | 142 | 119 | 118 | 71 | 116 | 142 | 169 | 149 | 158 | 185 | 168 |
Working Capital Days | 58 | 63 | 46 | 56 | 46 | 62 | 95 | 99 | 79 | 95 | 112 | 95 |
ROCE % | 23% | 18% | 17% | 23% | 28% | 16% | 18% | 15% | 11% | 14% | 13% | 15% |
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Press Release / Media Release 3m
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 12 Apr
- Certificate Under Regulation 40(10) Of SEBI (LODR) Regulations, 2015 9 Apr
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 8 Apr
-
Compliance Certificate For The Financial Year Ended On March 31, 2024
4 Apr - Certificate under regulation 7(3) of the SEBI (LODR) Regulations, 2015 for the financial year ended March 31, 2024.
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2012
from nse
-
Financial Year 2011
from bse
-
Financial Year 2011
from nse
Concalls
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Sep 2023Transcript PPT
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Sep 2021TranscriptPPT
-
Aug 2021Transcript PPT
-
May 2021TranscriptPPT
-
Feb 2021TranscriptPPT
-
Jan 2021TranscriptNotesPPT
-
Oct 2020TranscriptPPT
-
Aug 2020TranscriptNotesPPT
-
Aug 2020Transcript PPT
-
Jun 2020TranscriptPPT
-
Mar 2020TranscriptPPT
-
Feb 2020TranscriptNotesPPT
-
Feb 2020TranscriptNotesPPT
-
Nov 2019TranscriptPPT
-
Jul 2019TranscriptPPT
-
Jun 2019Transcript PPT
-
Jan 2019TranscriptNotesPPT
-
Jan 2019TranscriptNotesPPT
-
Jun 2018TranscriptNotesPPT
-
May 2018TranscriptPPT
-
Nov 2017TranscriptNotesPPT
-
Sep 2017TranscriptNotesPPT
-
Jun 2017Transcript PPT
-
Mar 2017TranscriptNotesPPT
-
Feb 2017TranscriptNotesPPT
-
Jan 2017TranscriptPPT
-
Nov 2016Transcript PPT
-
May 2016Transcript PPT
One of the top five pharmaceutical companies in India.[1]